A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC

The purpose of this study is to observe and evaluate the efficacy and safety of camrelizumab combined with albumin paclitaxel and cisplatin as perioperative treatment of advanced esophageal squamous cell.

Trial Details

NCT ID
NCT05182944
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Zhengzhou University
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • A：non-pCR patients
  • B：non-pCR patients
  • A：pCR patients
  • B：pCR patients
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Aged 18-80 years, males or females；
  • Histologically or cytologically confirmed as ESCC；
  • Esophageal squamous cell carcinoma without anti-tumor treatment, and the clinical stage is T1b-2N+M0 or T3-4aN+/-M0 (AJCC/UICC TNM staging system 8…
  • It can provide tumor tissue for the detection of PD-L1 expression level;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →